Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Other Non-Current Liabilities data on file, last reported at $19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 31.09% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $19.4 million (up 31.09% YoY), and the FY2025 full-year result was $21.6 million, up 48.03% from the prior year.
• Other Non-Current Liabilities eased to $19.4 million in Q1 2026, from $21.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $28.5 million in Q2 2022 to a low of $7.2 million in Q3 2022.
• A 5-year average of $16.3 million and a median of $14.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 638.52% in 2022 and slumped 57.5% in 2023, its largest moves.
• Tracing VIR's Other Non-Current Liabilities over 5 years: stood at $24.9 million in 2022, then rose by 4.1% to $26.0 million in 2023, then plunged by 43.85% to $14.6 million in 2024, then surged by 48.03% to $21.6 million in 2025, then dropped by 10.01% to $19.4 million in 2026.
• Business Quant data shows VIR's Other Non-Current Liabilities at $19.4 million in Q1 2026, $21.6 million in Q4 2025, and $13.3 million in Q3 2025.